CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells

Abstract Recent advances in cancer cell biology have focused on histone deacetylase inhibitors (HDACi’s) because they target pathways critical to the development and progression of disease. In particular, HDACi’s can induce expression of epigenetically silenced genes that promote growth arrest, diff...

Full description

Saved in:
Bibliographic Details
Published inNeurobiology of disease Vol. 26; no. 3; pp. 671 - 680
Main Authors Gensert, JoAnn M, Baranova, Oxana V, Weinstein, David E, Ratan, Rajiv R
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.06.2007
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Recent advances in cancer cell biology have focused on histone deacetylase inhibitors (HDACi’s) because they target pathways critical to the development and progression of disease. In particular, HDACi’s can induce expression of epigenetically silenced genes that promote growth arrest, differentiation and cell death. In glioma cells, one such repressed gene is the tetraspanin CD81, which regulates cytostasis in various cell lines and in astrocytes, the major cellular component of gliomas. Our studies show that HDACi’s, trichostatin and sodium butyrate, promote growth arrest and differentiation with negligible cell death in glioma cells and induce expression of CD81 and cyclin-dependent kinase inhibitor 1A (p21CIP/WAF-1 ), another regulator of cytostasis in astrocytes. Interference RNA knock-down of CD81 abrogates cytostasis promoted by HDAC inhibition indicating that HDACi-induced CD81 is responsible for growth arrest. Induction of CD81 expression through HDAC inhibition is a novel strategy to promote growth arrest in glioma cells.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0969-9961
1095-953X
DOI:10.1016/j.nbd.2007.03.008